Which has better valuation & earnings, PHVS or PROK?

ProKidney has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A ProKidney $890K 588.51 -$68.99M -$0.53 N/A

Is PHVS or PROK more profitable?

Pharvaris has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% ProKidney -8,131.50% N/A -21.39%

Is PROK or NUVB more profitable?

Nuvation Bio has a net margin of -102.06% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -8,131.50% N/A -21.39% Nuvation Bio -102.06% -44.10% -23.80%

ProKidney (PROK) Competitors

$1.73 +0.03 (+2.00%)

As of 09:41 AM Eastern

Compare

PROK vs. PHVS, NTLA, AGIO, MLYS, and NUVB

Should you buy ProKidney stock or one of its competitors? MarketBeat compares ProKidney with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProKidney include Pharvaris (PHVS), Intellia Therapeutics (NTLA), Agios Pharmaceuticals (AGIO), Mineralys Therapeutics (MLYS), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.

How does ProKidney compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

51.6% of ProKidney shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pharvaris has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
ProKidney	-8,131.50%	N/A	-21.39%

ProKidney has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
ProKidney	$890K	588.51	-$68.99M	-$0.53	N/A

Pharvaris has a beta of -2.35, suggesting that its stock price is 335% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

In the previous week, Pharvaris had 3 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Pharvaris and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.87 beat Pharvaris' score of 0.69 indicating that ProKidney is being referred to more favorably in the news media.

Company	Overall Sentiment
Pharvaris	Positive
ProKidney	Very Positive

Pharvaris currently has a consensus target price of $49.64, indicating a potential upside of 47.60%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 326.76%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

ProKidney beats Pharvaris on 12 of the 16 factors compared between the two stocks.

How does ProKidney compare to Intellia Therapeutics?

ProKidney (NASDAQ:PROK) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Intellia Therapeutics has a net margin of -597.04% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

ProKidney has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	588.51	-$68.99M	-$0.53	N/A
Intellia Therapeutics	$66.09M	34.88	-$412.69M	-$3.54	N/A

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ProKidney has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

In the previous week, Intellia Therapeutics had 1 more articles in the media than ProKidney. MarketBeat recorded 2 mentions for Intellia Therapeutics and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.87 beat Intellia Therapeutics' score of 1.44 indicating that ProKidney is being referred to more favorably in the media.

Company	Overall Sentiment
ProKidney	Very Positive
Intellia Therapeutics	Positive

ProKidney currently has a consensus price target of $7.40, suggesting a potential upside of 326.76%. Intellia Therapeutics has a consensus price target of $20.46, suggesting a potential upside of 23.98%. Given ProKidney's stronger consensus rating and higher probable upside, equities research analysts clearly believe ProKidney is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

ProKidney beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ProKidney compare to Agios Pharmaceuticals?

ProKidney (NASDAQ:PROK) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

ProKidney has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	588.51	-$68.99M	-$0.53	N/A
Agios Pharmaceuticals	$54.03M	39.94	-$412.78M	-$7.25	N/A

ProKidney has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

In the previous week, ProKidney and ProKidney both had 1 articles in the media. ProKidney's average media sentiment score of 1.87 beat Agios Pharmaceuticals' score of 1.77 indicating that ProKidney is being referred to more favorably in the media.

Company	Overall Sentiment
ProKidney	Very Positive
Agios Pharmaceuticals	Very Positive

ProKidney currently has a consensus target price of $7.40, indicating a potential upside of 326.76%. Agios Pharmaceuticals has a consensus target price of $40.89, indicating a potential upside of 12.68%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

51.6% of ProKidney shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Agios Pharmaceuticals has a net margin of -639.84% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Summary

ProKidney beats Agios Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does ProKidney compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Mineralys Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
ProKidney	-8,131.50%	N/A	-21.39%

ProKidney has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
ProKidney	$890K	588.51	-$68.99M	-$0.53	N/A

In the previous week, Mineralys Therapeutics had 2 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Mineralys Therapeutics and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.87 beat Mineralys Therapeutics' score of 1.10 indicating that ProKidney is being referred to more favorably in the news media.

Company	Overall Sentiment
Mineralys Therapeutics	Positive
ProKidney	Very Positive

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mineralys Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Mineralys Therapeutics currently has a consensus price target of $49.33, indicating a potential upside of 87.09%. ProKidney has a consensus price target of $7.40, indicating a potential upside of 326.76%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

ProKidney beats Mineralys Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ProKidney compare to Nuvation Bio?

ProKidney (NASDAQ:PROK) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Nuvation Bio has a net margin of -102.06% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Nuvation Bio	-102.06%	-44.10%	-23.80%

ProKidney currently has a consensus target price of $7.40, indicating a potential upside of 326.76%. Nuvation Bio has a consensus target price of $12.50, indicating a potential upside of 121.79%. Given ProKidney's higher probable upside, research analysts clearly believe ProKidney is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Nuvation Bio had 9 more articles in the media than ProKidney. MarketBeat recorded 10 mentions for Nuvation Bio and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.87 beat Nuvation Bio's score of -0.26 indicating that ProKidney is being referred to more favorably in the media.

Company	Overall Sentiment
ProKidney	Very Positive
Nuvation Bio	Neutral

51.6% of ProKidney shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ProKidney has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

ProKidney has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	588.51	-$68.99M	-$0.53	N/A
Nuvation Bio	$62.90M	31.20	-$204.63M	-$0.43	N/A

Summary

ProKidney beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$519.24M	$3.02B	$6.61B	$12.27B
Dividend Yield	N/A	1.78%	2.68%	5.90%
P/E Ratio	-3.24	18.82	25.76	23.98
Price / Sales	588.51	332.02	550.19	97.97
Price / Cash	N/A	56.53	46.33	53.91
Price / Book	-0.52	4.12	10.57	6.32
Net Income	-$68.99M	$64.45M	$3.57B	$337.22M
7 Day Performance	-5.25%	0.08%	0.76%	-1.25%
1 Month Performance	2.60%	-0.44%	0.19%	-0.63%
1 Year Performance	139.87%	23.45%	30.79%	27.95%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	2.2351 of 5 stars	$1.73 +2.0%	$7.40 +326.8%	+120.5%	$519.24M	$890K	N/A	3	Positive News
PHVS Pharvaris	3.4233 of 5 stars	$33.29 +0.3%	$49.18 +47.7%	+89.6%	$2.17B	N/A	N/A	30	Analyst Forecast
NTLA Intellia Therapeutics	3.0447 of 5 stars	$15.50 +1.6%	$20.46 +32.0%	+67.7%	$2.13B	$67.67M	N/A	600
AGIO Agios Pharmaceuticals	2.5636 of 5 stars	$36.28 +1.9%	$40.89 +12.7%	+10.7%	$2.12B	$54.03M	N/A	390	Positive News Analyst Forecast
MLYS Mineralys Therapeutics	4.5391 of 5 stars	$25.86 +1.0%	$49.33 +90.7%	+85.0%	$2.11B	N/A	N/A	28	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. PHVS, NTLA, AGIO, MLYS, and NUVB

How does ProKidney compare to Pharvaris?

Summary

How does ProKidney compare to Intellia Therapeutics?

Summary

How does ProKidney compare to Agios Pharmaceuticals?

Summary

How does ProKidney compare to Mineralys Therapeutics?

Summary

How does ProKidney compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. PHVS, NTLA, AGIO, MLYS, and NUVB

How does ProKidney compare to Pharvaris?

Do insiders & institutionals believe in PHVS or PROK?

Is PHVS or PROK more profitable?

Which has better valuation & earnings, PHVS or PROK?

Which has more risk and volatility, PHVS or PROK?

Does the media refer more to PHVS or PROK?

Do analysts prefer PHVS or PROK?

Summary

How does ProKidney compare to Intellia Therapeutics?

Is PROK or NTLA more profitable?

Which has preferable earnings & valuation, PROK or NTLA?

Do insiders and institutionals hold more shares of PROK or NTLA?

Which has more volatility & risk, PROK or NTLA?

Does the media prefer PROK or NTLA?

Do analysts recommend PROK or NTLA?

Summary

How does ProKidney compare to Agios Pharmaceuticals?

Which has higher earnings & valuation, PROK or AGIO?

Which has more risk & volatility, PROK or AGIO?

Does the media prefer PROK or AGIO?

Do analysts rate PROK or AGIO?

Do insiders & institutionals believe in PROK or AGIO?

Is PROK or AGIO more profitable?

Summary

How does ProKidney compare to Mineralys Therapeutics?

Is MLYS or PROK more profitable?

Which has stronger earnings & valuation, MLYS or PROK?

Does the media favor MLYS or PROK?

Do institutionals and insiders believe in MLYS or PROK?

Which has more risk and volatility, MLYS or PROK?

Do analysts rate MLYS or PROK?

Summary

How does ProKidney compare to Nuvation Bio?

Is PROK or NUVB more profitable?

Do analysts recommend PROK or NUVB?

Does the media refer more to PROK or NUVB?

Do institutionals and insiders believe in PROK or NUVB?

Which has more volatility & risk, PROK or NUVB?

Which has higher earnings and valuation, PROK or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools